Retatrutide's blockbuster potential questioned
The Mizuho analyst expressed skepticism that Eli Lilly's retatrutide will be the massive blockbuster investors expect, viewing its ~30% weight loss as incremental and potentially cannibalistic.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.